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ABSTRACT
Human cytomegalovirus (HCMV) infection is the single most frequent infectious complication in the
early period after kidney transplantation. The HCMV load in blood, measured by HCMV PCR or the
HCMV pp65 antigen test, is a predictor of HCMV disease in seropositive recipients. However, plasma
virus load measurements are of only modest value in predicting the risk of HCMV disease in
seronegative recipients of kidneys from seropositive donors. HCMV infection is an independent risk-
factor for acute kidney graft rejection. There is also evidence that HCMV is associated with an increased
long-term mortality and post-transplant diabetes mellitus. Whether pre-emptive or prophylactic therapy
should be the preferred strategy is not yet decided. Some studies indicate that HCMV prophylaxis may
reduce the risk of acute rejection, and thereby increase long-term graft survival in seronegative
recipients of kidneys from seropositive donors.
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INCIDENCE AND DEFINITION OF
HUMAN CYTOMEGALOVIRUS
INFECTION AND DISEASE
Human cytomegalovirus (HCMV) is the single
most frequent cause of infectious complications in
the early period after kidney transplantation, with
overall incidences of HCMV infection and disease
during the first 100 days post-transplantation of c.
60% and 25%, respectively, when no HCMV
prophylaxis or pre-emptive therapy is given [1–4].
The frequency of HCMV infection is the same for
HCMV IgG-seronegative recipients (R–) with
seropositive donors (D+) (primary infection) as
for pre-transplant seropositive recipients (R+),
whereas HCMV disease is nearly three-fold more
frequent in the serostatus group D+ ⁄R– than for
D+/R+ [2,4].
HCMV infection is defined as isolation of
HCMV, or detection of HCMV proteins or nucleic
acid, in any body fluid or tissue specimen [5].
HCMV disease is defined as detection of HCMV
in a clinical specimen, accompanied by either
HCMV syndrome with fever, muscle pain, leu-
kopenia and ⁄ or thrombocytopenia (other causes
excluded), or by organ involvement, such as
hepatitis, gastrointestinal ulceration, pneumoni-
tis, retinitis, central nervous system disease,
nephritis, myocarditis, cystitis or pancreatitis [5].
DIAGNOSTIC TESTS
Conventionally, HCMV infection has been diag-
nosed by serology, defined as seroconversion of
anti-HCMV IgG and IgM antibodies (for primary
HCMV infection), and by a significant rise in IgG
antibodies (for secondary infection). Today, sero-
logical tests are of importance for the assessment
of the serological status of organ transplant
recipients at the time of transplantation, thus
defining the risk for HCMV disease, but have
little diagnostic value thereafter.
‘Viraemia’ is defined by the isolation of HCMV
by culture involving the use of either standard
cell culture or shell vial culture techniques [5].
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‘Antigenaemia’ is defined by the detection of
HCMV pp65 antigen in leukocytes, while ‘DNae-
mia’ is defined by the detection of HCMV DNA in
samples of plasma, whole blood or isolated
peripheral blood leukocytes, measured by a
nucleic acid amplification technique such as
PCR [5]. Tests for detection of antigenaemia or
DNaemia are far more sensitive than virus isola-
tion from blood. Finally, ‘RNaemia’ is defined by
the detection of RNA in samples of whole blood,
isolated peripheral leukocytes or buffy coat spec-
imens [5]. There is a good correlation [6] between
the presence of pp67 mRNA and pp65 antigen-
aemia of > 10 positive cells ⁄ 100 000 leukocytes.
THE PREDICTIVE VALUE OF HCMV
PP65 ANTIGENAEMIA AND HCMV
DNA LOAD
Kidney graft recipients with HCMV disease have
significantly higher maximum HCMV pp65
counts than those who remain asymptomatic
[4,7–9]. This is also true when the serostatus
groups D+ ⁄R+ and D– ⁄R+ are considered sepa-
rately, but is not true in the D+ ⁄R– serostatus
group [4]. This indicates that the number of cells
positive for HCMV pp65 is a better predictor of
HCMV disease in reactivated than in primary
HCMV infection. Among HCMV-seropositive
recipients, 50% developed HCMV disease with
maximum HCMV pp65 antigen counts of at least
25 ⁄ 100 000 leukocytes [4] (Fig. 1). In the D+ ⁄R–
serostatus group, > 80% of those with an HCMV
pp65 count of ‡ 1 ⁄ 100 000 leukocytes developed
HCMV disease. However, the practical applica-
tion of measuring peak virus loads is limited
because the maximum is often reached after the
appearance of HCMV disease. In accordance with
the above results, Humar et al. [10] concluded that
routine monitoring would have predicted disease
in only 38% of seronegative recipients with
seropositive donors, indicating that plasma virus
load measurements are of only modest value in
this patient group.
In contrast, Hassan-Walker et al. [8] used data
from a much smaller study of 87 renal allograft
recipients to underline the importance of virus
load in patients with primary infection. Peak
HCMV load was one of the covariates in a
multivariate logistic regression analysis of risk-
factors for HCMV disease, irrespective of whether
peak load occurred before or after the initiation of
HCMV disease. However, it is not feasible for a
peak virus load occurring after the initiation of
HCMV disease to be a risk-factor for disease, so
the statistics used in this study may be inappro-
priate. Furthermore, in a study of 52 solid-organ
recipients with HCMV disease, Humar et al. [11]
found that virus load half-life was significantly
longer in patients with recurrence than in those
without recurrence of disease, and also found that
failure to clear virus was predictive of relapse.
HCMV INFECTION AND DISEASE
In multivariate analyses, episodes of acute clinical
rejection and recipient age are independent risk-
factors for HCMV infection, while independent
risk-factors for HCMV disease are episodes of
acute clinical rejection and the serostatus group
D+ ⁄R– [4,12]. The fact that the serostatus group
D+ ⁄R– is a risk-factor for HCMV disease is
accepted widely [13]. The large United States
Renal Data System study reported significantly
more HCMV disease in D+ ⁄R– patients compared
to all other kidney transplant recipients (inclu-
ding D– ⁄R–) [14]. However, it seems inappro-
priate to include D– ⁄R– patients as a control
Fig. 1. The percentage of first renal graft recipients
(n = 397) who developed human cytomegalovirus
(HCMV) disease as a function of the maximum HCMV
pp65 antigen count before or during HCMV disease. The
upper curve represents seronegative recipients with sero-
positive donors (D+ ⁄R–; n = 72) and the lower curve
represents seropositive recipients (R+; n = 286). For in-
stance, in R+ patients with a maximum HCMV pp65
antigen count ‡ 1, the risk of HCMV disease is 29%. In
D+ ⁄R– patients with a maximum HCMV pp65 antigen
count ‡ 1, the risk is 82%. (Taken from the study of Sagedal
et al. [4] and printed with permission from Lippincott
Williams & Wilkins.)
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group for D+ ⁄R– patients, since D– ⁄R– patients
very seldom become infected by HCMV with
development of HCMV disease.
Steroid-resistant rejection is also a risk-factor
for HCMV disease [15,16]. The risk of HCMV
disease associated with anti-thymocyte globulin
and muromonab-CD3 (OKT3) is higher when
these agents are given as treatment of rejection
than when they are used for induction therapy
[17].
When evaluating risk-factors for HCMV dis-
ease in 87 kidney transplant recipients, Emery
et al. [18] found that donor ⁄ recipient serostatus
and receipt of anti-thymocyte globulin for rejec-
tion were only of borderline significance in
univariate analyses, and both became non-signi-
ficant after adjustment for initial HCMV load. The
authors considered that the classical risk-factors
of donor ⁄ recipient serotatus were explained
entirely by virus load. However, logistic regres-
sion analysis was used, irrespective of the fact
that HCMV disease appeared at different time-
points after transplantation. ‘Initial virus load’ is
also a time-dependent covariate, which can some-
times be measured only after the appearance of
HCMV disease. In addition, the authors did not
state whether only anti-thymocyte globulin ther-
apy preceding HCMV disease was included. Cox
regression analysis would probably be a more
appropriate statistical method to use. In a much
smaller study [19], a high initial plasma HCMV
DNA load, but not the initial HCMV pp65 count,
was highly predictive of development of HCMV
disease, although multivariate analyses were not
performed.
Several studies have reported an increased
incidence of HCMV disease in patients receiving
mycophenolate mofetil (MMF) [14,20,21]. In the
USA renal transplant MMF study [22], there was a
trend towards a higher incidence of HCMV
tissue-invasive disease in the MMF groups given
2 g and 3 g, compared to the group given
azathioprine, but the difference was not statisti-
cally significant. However, this study was statis-
tically powered to find differences in graft
rejection, not in HCMV disease. Also, in the
European and tricontinental MMF studies [23,24],
the frequency of HCMV tissue-invasive disease
was highest in the MMF group given 3 g. Other
studies have failed to show any association
between maintenance MMF treatment and an
increased frequency of HCMV disease [12,25,26].
Interestingly, Giral et al. [25] found that HCMV
disease was associated strongly with uncensored
graft loss only in the group treated with
azathioprine. In this study, all patients with
HCMV disease were treated with ganciclovir for
14 days. It has been postulated that a reported
MMF-induced enhanced anti-herpes virus activ-
ity of ganciclovir could contribute to the favour-
able effect on graft survival in the MMF-treated
group [27].
THE IMPACT OF HCMV INFECTION
AND DISEASE ON ACUTE REJECTION
EPISODES
Several studies have shown that HCMV is a risk-
factor for episodes of acute rejection [2,28–30]. In
three of these studies, the diagnosis of HCMV
infection was based upon positive culture or
seroconversion [2,29,30]. The results of clinical
studies investigating HCMV as a risk-factor for
acute renal graft rejection are summarised in
Table 1.
Two other studies implicate HCMV infection
indirectly as a risk-factor for episodes of acute
rejection [30,31]. Lowance et al. [31] showed that
Table 1. Clinical studies investi-
gating human cytomegalovirus
(HCMV) as a risk-factor for episodes
of acute rejection in kidney trans-
plant recipients
Study design
Number
of patients Results Reference
Retrospective 1424 HCMV disease was associated significantly with subsequent
biopsy-proven acute rejection
[92]
Prospective 451 Both HCMV infection (positive pp65 antigen) and HCMV
disease were independent predictors of clinical
acute rejections. HCMV disease was an independent predictor
of tubulointerstitial acute rejection
[28]
Retrospective 192 HCMV disease, but not asymptomatic HCMV infection,
was associated significantly with biopsy-verified acute rejection
[2]
Prospective 170 HCMV infection, but not HCMV disease, was associated
significantly with subsequent episodes of clinical acute rejection
[29]
Prospective 84 Clinical and biopsy-proven rejections were as frequent in the
HCMV risk group (D+ and ⁄ or R+) during the first 4 months
after transplantation and at 5-year follow-up as in the
D– ⁄R– risk group
[93]
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rejections were reduced by 50% in the D+ ⁄R–
serostatus group by valacyclovir prophylaxis
following transplantation for 90 days. Similarly,
in a retrospective register study by Opelz et al.
[32], an inhibitory effect of HCMV prophylaxis on
acute rejection was suggested. Among seronega-
tive recipients with seropositive donors with a
functioning graft after 1 year, significantly fewer
patients received rejection treatment in the pre-
ceding year (26.3% vs. 32.4%; p < 0.0001) in the
group that received HCMV prophylaxis. How-
ever, the duration of HCMV prophylaxis and the
antiviral agents used were not stated.
HCMV infection in the transplanted kidney
may result in HCMV inclusions in capillary
endothelial cells and tubular epithelial cells, as
seen by light microscopy [26,33]. The HCMV
inclusions may or may not be accompanied by
interstitial nephritis [26,34]. However, even with
elevated serum creatinine and apparent HCMV
disease, HCMV inclusions are detected in < 1% of
kidney allograft biopsy specimens [26]. The
results of sensitive methods, e.g., tissue HCMV
PCR, may be positive even in the absence of
HCMV inclusions, indicating that HCMV nephro-
pathy is much more common than reported
previously [35]. HCMV infection of the transplan-
ted kidney may itself contribute to graft dysfunc-
tion with an elevated serum creatinine level, and
improvement following treatment with ganciclo-
vir (without treatment for rejection) has been
described [26,36]. Moreover, it has been reported
that ganciclovir treatment (without specific anti-
rejection therapy) improved renal function in
renal transplant recipients with asymptomatic
HCMV infection and biopsy-proven late acute
rejection [37].
HCMV infection of the kidney may also result
in direct endothelial injury, with subsequent
HCMV glomerulopathy [36,38]. A prompt decline
in serum creatinine levels after institution of
intravenous ganciclovir (without anti-rejection
therapy) has also been described in patients with
HCMV glomerulopathy, but without tubulointer-
stitial changes [38]. In the study of Boyce et al.
[39], no correlation was found between acute
transplant glomerulopathy and HCMV infection
diagnosed by seroconversion and viraemia. How-
ever, immunohistochemical staining of the allo-
graft tissue to confirm the presence of HCMV was
not performed.
Finally, with HCMV infection, a granular pat-
tern of HCMV antigen may be seen in the
mesangium [36]. Thus, although rejection before
virus infection is the most frequent occurrence,
virus infection may certainly precede rejection.
However, Humar et al. [40] showed that HCMV
disease was a risk-factor for chronic rejection only
in the presence of acute rejection.
IMPACT OF HCMV INFECTION AND
DISEASE ON LONG-TERM PATIENT
SURVIVAL
As summarised in Table 2, HCMV disease in the
early post-transplant period has a detrimental
effect on long-term recipient survival in kidney
transplant recipients, and Sagedal et al. [41] dem-
onstrated, for the first time, that asymptomatic
HCMV infection in the early post-transplant
period was an independent risk-factor for overall
long-term mortality. The mechanisms for the
increase in overall long-term mortality caused
by HCMV are not fully understood. Nephroscle-
rosis, diabetic nephropathy and amyloidosis
causing renal insufficiency are known to be
associated with an increased risk of death after
transplantation [42–44]. However, the relative
prevalences of these diagnoses are the same
among patients who develop HCMV infection
and those who do not (personal unpublished
data).
Table 2. Clinical trials studying the
impact of human cytomegalovirus
(HCMV) infection and disease on
long-term patient survival in kidney
transplant recipients
Study design
Number
of patients Results Reference
Retrospective;
register study
33 479 Hospitalisation for HCMV disease was associated
independently with decreased all-cause patient survival
[14]
Prospective 471 Both asymptomatic HCMV infection and HCMV disease
during the first 100 days after transplantation were
associated significantly with increased overall patient
mortality beyond 100 days in multivariate analysis
[41]
Prospective 276 Overt HCMV disease was associated significantly with
decreased patient survival in univariate analysis
[94]
Prospective 85 HCMV disease during the first 4 months after
transplantation was associated significantly with
subsequent increased patient mortality in multivariate analysis
[95]
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It has been postulated previously that overt
HCMV disease may cause post-transplant diabe-
tes mellitus through both impaired b-cell function
and insulin action [30,45,46]. Moreover, asympto-
matic HCMV infection is associated significantly
with post-transplant diabetes mellitus [47]. This
raises the question of whether the occurrence of
diabetes mellitus contributes to the increased
mortality found in HCMV-infected renal trans-
plant patients. Unfortunately, the oral glucose
tolerance test was not used routinely during the
above-mentioned study (October 1994 to July
1997) [41], and such a hypothesis remains specu-
lative. However, HCMV viraemia has been asso-
ciated with death in paediatric lung transplant
recipients [48], and HCMV disease is a significant
risk-factor for patient death following liver trans-
plantation [49].
The association between HCMV and
cardiovascular risk
In heart transplant patients, HCMV infection has
been associated with accelerated coronary artery
atherosclerosis [50,51]. Also, in the native heart,
an association between HCMV antibodies and
coronary restenosis after atherectomy has been
described in many studies, although no associ-
ation has been found in others [8,29,31,52–55].
Similarly, an association between HCMV seropo-
sitivity and native atherosclerosis has been found
in some studies, but not in others [56,57]. Differ-
ent study designs may partly explain these
differing results. Interestingly, HCMV seroposi-
tivity in relatively young asymptomatic individ-
uals was found to be associated significantly with
endothelial dysfunction, but the association with
coronary artery calcification was not significant
[58]. Thus, the question of whether there is an
association between HCMV and native athero-
sclerosis is still unresolved.
IMPACT OF HCMV INFECTION AND
DISEASE ON LONG-TERM KIDNEY
GRAFT SURVIVAL
Clinical trials studying the association between
early HCMV infection and long-term kidney graft
survival are summarised in Table 3. Only a few
trials have investigated HCMV disease as a risk-
factor for death-censored graft loss (death with
functioning graft is excluded) [40,41,59]. Sagedal
et al. [41] were unable to demonstrate any detri-
mental effect of early asymptomatic HCMV infec-
tion or disease on death-censored graft loss.
However, Humar et al. [40] found that HCMV
disease was a significant risk-factor for death-
censored graft loss, but only in the presence of
acute graft rejection. In a retrospective study,
Nett et al. [59] found that HCMV disease was
Table 3. Clinical trials studying the
impact of human cytomegalovirus
(HCMV) infection and disease on
long-term kidney graft survival
Study design
Number
of patients Results Reference
Unknown 1339 HCMV disease increased the risk of death-censored
graft loss, but only in the presence of acute rejection
[40]
Prospective 471 Asymptomatic HCMV infection and HCMV disease
were both associated significantly with uncensored,
but not censored graft loss
[41]
Unknown 445 HCMV disease was an independent predictor of
uncensored graft loss in patients treated with azathioprine,
but not in those treated with mycophenolate mofetil
[25]
Retrospective 470 HCMV disease had a detrimental effect on uncensored
kidney graft survival, but only in recipients with zero
HLA-DR matches
[96]
Prospective 276 Overt HCMV disease was associated significantly with
decreased graft survival in univariate analysis. Graft
survival was not defined (censored vs. uncensored)
[94]
Prospective 85 HCMV disease during the first 4 months after
transplantation had no detrimental effect on graft
survival. Graft survival was not defined
(censored vs. uncensored)
[95]
Prospective 84 Uncensored graft survival was the same in the HCMV
risk group (D+ and ⁄ or R+) during the first 4 months
after transplantation and at 5-year follow-up as in the
D– ⁄R– risk group
[93]
Retrospective 2740 kidney and
606 pancreas–kidney
transplant recipients
HCMV disease was associated significantly with an
increased censored graft loss, but whether HCMV
disease was treated with a reduction in
immunosuppressive treatment was not stated
[59]
HLA-DR, tissue type donor ⁄ recipient.
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associated significantly with censored graft loss,
but it was not clear whether HCMV disease was
treated by a reduction in immunosuppressive
treatment, which might possibly explain the
increase in graft loss.
Several studies have investigated uncensored
graft failure (death with functioning graft is
included). As shown in Table 3, most studies
report a significant association between HCMV
disease and uncensored graft loss. Unfortunately,
some studies fail to define graft loss. It is obviously
important to define whether graft loss is censored
or uncensored to make comparisons meaningful.
ASSOCIATION BETWEEN HCMV AND
OTHER INFECTIOUS DISEASES
HCMV is known to predispose to opportunistic
superinfection with a range of different microor-
ganisms, including Pneumocyctis jiroveci (carinii), a
variety of fungi and Listeria monocytogenes, with a
marked decrease in CD4-positive cells and an
increase in CD8-positive cells in HCMV-infected
organ transplant recipients implying the highest
risk of opportunistic superinfection [60]. Another
possible mechanism of superinfection could
involve the disruption of mucosal surfaces by
HCMV, thereby increasing the risk of superinfec-
tion [5].
Interestingly, valacyclovir prophylaxis for
100 days (vs. placebo) resulted in a significantly
reduced incidence of non-herpes virus infections
in seronegative recipients of kidneys from sero-
positive donors [31]. Infections with Candida were
reduced significantly in the serostatus group
D+ ⁄R– receiving valacyclovir, and the reduction
in staphylococcal infections in the same patient
group nearly reached statistical significance [31].
The association between HCMV and other
herpes viruses
Human herpes virus 6 (HHV-6) is detected during
the first 4 weeks after solid-organ or bone marrow
transplantation [61,62]. Based on serology, HHV-6
reactivation after kidney transplantation was asso-
ciated significantly with primary HCMV infection
and HCMV syndrome [61]. However, serological
cross-reactions between HHV-6 and HHV-7 exist,
and serology alone is unable to discriminate
between the roles of these two herpes viruses
[63]. Based on detection of HCMV, HHV-6 and
HHV-7 DNA in peripheral blood leukocytes,
HHV-7, but not HHV-6, was associated signifi-
cantly with HCMV disease [63]. However, the
small number of patients in the study with
detectable HHV-6 DNA (n = 7) may explain why
no association was found between HHV-6 and
HCMV disease. Nevertheless, the result is in
accordance with another study of renal transplant
recipients in which a significant association
between HCMV disease and detection of HHV-7
DNA was found, while that with HHV-6 DNA
was inconclusive [64]. During the first 120 days
following kidney transplantation, HCMV, HHV-7
and HHV-6 DNaemia were present in 58%, 46%
and 23% of patients, respectively [65]. Moreover,
the HCMV virus load was significantly higher
than that of either HHV-7 or HHV-6, and there
was a significant increase in HCMV disease in
patients with HCMV and HHV-7 co-infection.
In liver transplant recipients, there was a
clustering of high HHV-6 and HHV-7 virus loads
in the HCMV D+ ⁄R– serostatus subgroup, indi-
cating that HHV-6 and HHV-7 replication depend
on the level of HCMV replication [66]. Moreover,
intravenous ganciclovir reduced the load of both
HCMV, HHV-6 and HHV-7, confirming the effect
of ganciclovir on HHV-6 and HHV-7.
In addition, there have been several reports of
an association between HCMV and Epstein–Barr
virus (EBV). In a study of 208 renal transplant
recipients followed for 3 years, HCMV and EBV
replication often overlapped in time, but HCMV
replication mostly preceded EBV replication,
indicating that HCMV replication may induce
activation of latent EBV infection [67]. EBV infec-
tion is associated with development of post-
transplant lymphoproliferative disease (PTLD),
which occurs in c. 2% of all transplant patients. In
pre-transplant EBV-seronegative liver transplant
recipients, HCMV disease was the only factor
associated significantly with the development of
PTLD in multivariate analysis [68]. However, in a
large study of renal transplant patients compri-
sing both EBV-seropositive and -seronegative
individuals, an EBV-seronegative status at trans-
plant was the only factor associated significantly
with development of PTLD, and HCMV disease
was not a risk-factor for PTLD in univariate or
multivariate analyses [69]. Malouf et al. [70]
found that anti-herpes virus prophylaxis in
EBV-seronegative lung transplant recipients
reduced the incidence of PTLD significantly.
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PREVENTION OF HCMV DISEASE
Pre-emptive anti-HCMV therapy
With a pre-emptive anti-HCMV therapeutic regi-
men, an antiviral agent is introduced at the first
sign of HCMV antigenaemia, positive HCMV
PCR, or positive HCMV viraemia. Frequent mon-
itoring of HCMV in blood is thus an important
part of such a regimen. One possible advantage
with this therapeutic regimen, compared to pro-
phylaxis, is that fewer patients are exposed to
antiviral agents, resulting in less drug resistance.
Clinical trials investigating the effect of pre-
emptive anti-HCMV therapy in kidney transplant
recipients are summarised in Table 4. There are
fewer studies investigating pre-emptive, as
opposed to prophylactic, anti-HCMV therapy in
renal transplant recipients. Moreover, the HCMV
diagnostic techniques and therapeutic regimens
differ among various trials, making comparisons
somewhat difficult. Some studies on pre-emptive
anti-HCMV therapy in liver transplant patients
are therefore also discussed to elucidate clinical
aspects associated with this therapeutic strategy.
In the study by Singh et al. [71] of 47 liver
transplant patients, intravenous ganciclovir was
given to the experimental group for 7 days
following a positive HCMV culture, while the
control group received high-dose acyclovir dur-
ing the first 24 weeks post-transplantation.
HCMV disease was reduced significantly in the
ganciclovir-treated group, and it was concluded
that oral acyclovir was ineffective as prophylaxis
against HCMV disease in liver transplant
patients. Oral ganciclovir given pre-emptively to
kidney transplant patients upon detection of
HCMV pp65 antigenaemia during the first
12 weeks post-transplantation (minimum treat-
ment duration of 4 weeks) is also highly effective
in preventing HCMV disease [72]. Furthermore,
the incidence of late occurrence of HCMV disease
was the same in the treatment and control groups,
indicating that HCMV disease is prevented and
not simply delayed by early pre-emptive therapy.
In a prospective, randomised study of 60 liver
transplant patients [73], oral ganciclovir was given
pre-emptively for 14 days following detection of
HCMV pp65 antigenaemia. There was no differ-
ence in the incidence of HCMV disease between
the treatment group and the control group,
although the short treatment period of 14 days
may have contributed to the lack of efficacy
observed for pre-emptive treatment. In contrast,
oral ganciclovir given pre-emptively for a median
duration of 49 days in kidney transplant recipients
was highly effective in reducing HCMV disease
[72]. However, in the study of Rayes et al. [73], 28
(32%) of 88 patients were not randomised because
of HCMV disease preceding antigenaemia. This
may be explained by the fact that a positive test
was defined as at least one HCMV pp65-positive
cell ⁄ 10 000 leukocytes (compared to at least one
HCMV pp65-positive cell ⁄ 100 000 leukocytes
[72]). This higher cut-off level may explain why
HCMV disease preceded HCMV antigenaemia
more often in that study (7.5% of all observed
patients vs. 1.8% of all observed patients [72,73]).
These observations demonstrate that frequent
Table 4. Clinical trials investigating
the effect of pre-emptive anti-human
cytomegalovirus (HCMV) therapy
in kidney transplant recipients
Study design Number of patients Results Reference
Retrospective,
uncontrolled
87 + 82 with no
HCMV infection
Ganciclovir given for 14 days following
detection of positive viraemia in 87 patients
resulted in the same uncensored graft loss and
patient mortality after follow-up for 5 years
as in 82 patients with no HCMV infection
[74]
Prospective,
randomised,
comparative
83 Oral ganciclovir given following detection of
HCMV pp65 antigenaemia during the first
12 weeks post-transplantation (minimum
treatment duration of 4 weeks) is highly
effective in preventing HCMV disease
[72]
Prospective,
randomised,
comparative
36 Intravenous ganciclovir given for 21 days
following detection of HCMV viraemia
(15 patients) decreased HCMV disease in
the pre-emptively treated group, compared
to deferred therapy (21 patients), but the
difference was not significant
[97]
Prospective,
non-randomised,
uncontrolled
35 Intravenous ganciclovir was given for 2–3 weeks
following detection of HCMV antigenaemia,
and no patients developed HCMV disease
[98]
Prospective,
randomised,
placebo-controlled
Ten kidney and
two liver transplant
recipients
Intravenous ganciclovir given for 2 weeks
(n = 5) following detection of HCMV
antigenaemia reduced HCMV disease
significantly
[99]
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monitoring for HCMV infection is mandatory with
a pre-emptive therapeutic regimen.
The study of Akposso et al. [74] (Table 4) com-
pared a pre-emptive treatment group of patients
with a control group who were not suffering from
HCMV infection, so the conclusion that ganciclovir
given pre-emptively may reduce HCMV-induced
graft loss may be based on false assumptions.
Risk adaptive strategies have been used in
some studies, in which ganciclovir was adminis-
tered while the patients also received anti-lym-
phocyte antibodies for induction therapy or
steroid-resistant rejections, irrespective of HCMV
viraemia or antigenaemia [75–77]. However, the
therapeutic strategy in all these studies involved
targeted prophylaxis rather than pre-emptive
therapy, and HCMV disease was reduced signi-
ficantly in the patients treated with ganciclovir.
Prophylactic anti-HCMV therapy
With a prophylactic anti-HCMV therapeutic regi-
men, the antiviral agent is introduced to a large
patient population before any signs of active
HCMV infection, and frequent HCMV monitoring
is not mandatory. Antiviral agents used prophy-
lactically against HCMV are acyclovir ⁄ valacyclo-
vir and ganciclovir ⁄ valganciclovir. An HCMV
protein kinase (a UL97 gene product) phosphory-
lates ganciclovir to ganciclovir monophosphate,
which is converted subsequently by cellular
enzymes to ganciclovir triphosphate, the biolo-
gically effective compound [78]. Interestingly,
acyclovir is phosphorylated far less efficiently
than is ganciclovir by the HCMV UL97
enzyme [79]. Thus, acyclovir and valacyclovir
are ineffective in inhibiting HCMV replication,
and therefore have no place in pre-emptive anti-
HCMV therapy or in the treatment of HCMV
disease. However, given prophylactically, they
reduce HCMV disease significantly in kidney
transplant recipients.
Selected clinical trials investigating the effect of
prophylactic anti-HCMV therapy in kidney trans-
plant recipients are summarised in Table 5. Pro-
phylactic oral valacyclovir yields increased
acyclovir exposure compared to oral acyclovir,
and reduces HCMV disease effectively [31]. Oral
acyclovir has also been shown to be effective in
reducing HCMV disease in some studies, but not
in others (Table 5). In contrast, HCMV prophy-
laxis with oral ganciclovir is reported to be
superior to oral acyclovir in reducing HCMV
disease [13,80]. In one of these studies, the dose of
oral acyclovir was only 400 mg three-times-daily,
while high-dose oral acyclovir was given (up to
3200 mg ⁄day) in the other study.
Valganciclovir has now increasingly replaced
oral ganciclovir because of its higher bioavaila-
bility, and has been shown to be as efficient as
oral ganciclovir in reducing HCMV disease in
solid-organ recipients [81]. However, only one-
third of the patients were kidney transplant
recipients, and the study was not designed or
powered to show an overall reduction in the
incidence of HCMV disease with valganciclovir
compared with oral ganciclovir. Interestingly, a
meta-analysis of 12 randomised trials showed that
acyclovir (including valacyclovir) prophylaxis in
solid-organ transplant patients was associated
significantly with reductions in HCMV disease
and patient mortality [82]. Prophylaxis resulted in
Table 5. Selected clinical trials investigating the effect of prophylactic anti-human cytomegalovirus (HCMV) therapy in
kidney transplant recipients
Study design Number of patients Results Reference
Prospective, randomised,
placebo-controlled
616: 135 valacyclovir; 120 placebo Valacyclovir prophylaxis (2000 mg four-times-daily)
for 90 days post-transplantation delayed and reduced
HCMV disease significantly compared to deferred therapy
[31]
Prospective, randomised,
placebo-controlled
104: 53 acyclovir; 51 placebo Prophylaxis with oral acyclovir 800–3200 mg ⁄day for
12 weeks post-transplantation reduced HCMV disease
significantly during the first year
[100]
Prospective, randomised
not placebo-controlled
44: 22 ganciclovir; 22 controls Oral ganciclovir (750 mg twice-daily) for 3 months
reduced HCMV infection significantly within the first
9 months after transplantation compared to no prophylaxis
[101]
Prospective, randomised,
not placebo-controlled
32 (only D+ ⁄R–):22 acyclovir; 10 controls No beneficial effect of oral acyclovir (800–3200 mg ⁄day)
for the first 12 weeks compared with no prophylaxis
[102]
Prospective, randomised,
comparative
42:19 ganciclovir; 23 acyclovir Oral ganciclovir (1000 mg three-times-daily) for the first
12 weeks reduced HCMV disease significantly compared
to oral acyclovir (200 mg twice-daily)
[103]
Prospective, randomised,
not placebo-controlled
32 (only D+ ⁄R–):17 ganciclovir; 15 controls Intravenous ganciclovir from day 14 to day 28 after
transplantation delayed the time to HCMV infection
significantly, but did not decrease HCMV disease
[104]
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a 40% reduction in overall mortality. Moreover,
prophylaxis was associated with a significant
reduction in opportunistic infections and acute
graft rejection. During prophylactic treatment,
valacyclovir was superior to high-dose acyclovir
in reducing HCMV disease.
In another meta-analysis of 13 studies, anti-
HCMV prophylaxis was associated significantly
with reduced HCMV disease [83]. In contrast to
the meta-analysis described above, most of the
studies analysed used ganciclovir prophylaxis.
Prophylactic treatment reduced graft loss and
patient mortality by 22% and 20%, respectively,
but statistical significance was not achieved.
There was no effect of prophylactic treatment on
the incidence of episodes of acute rejection.
Snydman et al. [84] found that intravenous
HCMV immunoglobulin reduced HCMV disease
significantly in seronegative recipients with sero-
positive donors. However, with the antiviral
agents available today, the role of intravenous
immunoglobulin is reduced.
Seronegative recipients with seropositive
donors have been a matter of concern. In a study
of 41 renal transplant recipients of the serostatus
D+ ⁄R– group, only 40% of those who developed
HCMV disease were HCMV PCR-positive before
the disease [85]. Based on the assumptions made,
the authors indicated that the deferred strategy
and the pre-emptive strategy are slightly less costly
than the prophylactic strategy. However, accord-
ing to European best-practice guidelines, HCMV
prophylaxis for kidney transplant recipients in the
serostatus D+ ⁄R– group is recommended [86].
Interestingly, in a retrospective register study
by Opelz et al. [32], HCMV prophylaxis resulted
in significantly increased censored and uncen-
sored graft survival in seronegative recipients
with seropositive donors (D+ ⁄R–). Moreover,
HCMV prophylaxis resulted in significantly bet-
ter patient survival in the serostatus D+ ⁄R–
group. However, the antiviral agents used and
the duration of HCMV prophylaxis were not
stated. Further prospective, randomised studies
are needed to fully evaluate the effect of HCMV
prophylaxis on acute rejection, graft loss and
long-term patient mortality.
Ganciclovir resistance
A potential drawback with prolonged use of anti-
HCMV agents is increased virus drug resistance.
Limaye et al. [87] reported that 7% of 240 solid-
organ recipients who received oral ganciclovir
prophylactically for the first 100 days had ganci-
clovir-resistant HCMV disease, with all cases
occurring in seronegative recipients with sero-
positive donors. Ganciclovir resistance after vala-
cyclovir prophylaxis in a renal transplant
recipient has also been reported [88]. In another
study [89], 301 seronegative solid-organ recipients
with seropositive donors received either valganci-
clovir or oral ganciclovir prophylaxis for 90–
100 days after transplantation. The incidence of
HCMV UL97 mutations was 1.9% at the end of
prophylaxis, and 6.1% for patients with suspected
HCMV disease up to 1 year after transplantation
in the oral ganciclovir group. No resistance
mutations were detected in valganciclovir-treated
patients. However, in AIDS patients with HCMV
retinitis who received long-term valganciclovir
therapy, the cumulative incidence of patients
carrying viruses with UL97 mutations was 2.2%,
6.5%, 12.8% and 15.3% after 3, 6, 12 and
18 months of treatment, respectively [90]. Simi-
larly, a high incidence (9%) of ganciclovir-resist-
ant HCMV infection was found in lung transplant
recipients given intravenous ganciclovir pre-
emptively [91].
CONCLUSIONS
According to many authors, anti-HCMV prophy-
laxis may be the preferred therapeutic strategy for
seronegative recipients with seropositive donors.
Whether prophylaxis or pre-emptive therapy
should be the preferred strategy for seropositive
recipients is still a matter of debate. Some trans-
plantation centres keep the patients for only a few
weeks after transplantation, and therefore do not
favour pre-emptive therapy because of infrequent
HCMV monitoring. Both oral ganciclovir and
valacyclovir are superior to oral acyclovir as anti-
HCMV prophylaxis. Valganciclovir is at least as
effective as oral ganciclovir in reducing HCMV
disease, and seems to be associated with far fewer
resistance mutations. In seronegative recipients
with seropositive donors, there is some evidence
that anti-HCMV prophylaxis may reduce acute
kidney graft rejection and increase patient and
censored ⁄uncensored graft survival. On the other
hand, the data in the literature on the association
between pre-emptive anti-HCMV therapy and
patient and graft survival are scarce.
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Different designs and statistical tests used in the
various studies may to some degree account for
the divergent results.
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